Comparative Pharmacology
Head-to-head clinical analysis: CLOFIBRATE versus LOPID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOFIBRATE versus LOPID.
CLOFIBRATE vs LOPID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clofibrate is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and clearance of triglycerides-rich lipoproteins from plasma, and reduced hepatic secretion of VLDL.
Lopid (gemfibrozil) is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipoprotein lipase activity, reduced hepatic triglyceride secretion, and enhanced clearance of very-low-density lipoproteins (VLDL). It also increases high-density lipoprotein (HDL) cholesterol.
500-1000 mg orally twice daily, not to exceed 2 g daily.
600 mg orally twice daily, 30 minutes before morning and evening meals; maximum dose 1200 mg/day.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateTiclopidine + Tranilast
"Ticlopidine may increase the anticoagulant activities of Tranilast."
Clinical Note
moderateClopidogrel + Resveratrol
"Clopidogrel may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderateTiclopidine + Nimesulide
"Ticlopidine may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderateClopidogrel + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Clopidogrel."
Terminal elimination half-life 6-25 hours (mean 15 hours); may increase in renal impairment.
Terminal elimination half-life is approximately 1.5 hours in patients with normal renal function; clinical context: short half-life requires twice-daily dosing to maintain therapeutic levels; may be prolonged in renal impairment.
Approximately 60% renal as glucuronide conjugate; 40% biliary/fecal as unchanged drug and metabolites.
Primarily hepatic metabolism and renal excretion; approximately 70% of a dose is excreted in urine as unchanged drug and glucuronide conjugates, with ~30% excreted in feces via biliary elimination.
Category C
Category C
Fibrate Antihyperlipidemic
Fibrate Antihyperlipidemic